An O-Antigen Glycoconjugate Vaccine Produced Using Protein Glycan Coupling Technology Is Protective in an Inhalational Rat Model of Tularemia

Figure 2

Survival and disease progression of rats following an aerosol challenge with a range of doses of F. tularensis Schu S4. (a) F344 rats () were challenged via the aerosol route with a range of F. tularensis Schu S4 doses (see accompanying legend). Rats were monitored daily for mortality, and data were reported on the Kaplan-Meier survival curve. Calculated retained dose for each challenge group is shown on the Kaplan-Meier survival curve. (b) Clinical signs of disease were monitored twice daily. Average cumulative signs for each group are presented for animals which had not succumbed to disease. (c) Weight was monitored daily. Average weight change for each group is presented for animals which had not succumbed to disease. (d) Temperature was monitored twice daily. Average animal temperature for each group is presented for animals which had not succumbed to disease.

(a)

(b)

(c)

(d)